Website profile

The Manila Times

The Manila Times is a national daily newspaper in the Philippines that delivers trusted, quality content in print and digital editions.

  • 6,411articles · 30d
  • 1+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 91%with images
  • 271avg words
articles per day
Categories
  • Economy, Business & Finance 3,004
  • Finance & Business 2,326
  • News 1,954
  • Business & Industrial 778
  • Politics 628
  • Finance 563
  • Science & Technology 442
  • Arts, Culture, Entertainment & Media 431

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

The Manila Times
manilatimes.net > 09/09/2026 > tmt-newswire > globenewswire > inventiva-to-present-multiple-abstracts-at-paris-mash-2026 > 2421022 > amp

Inventiva to Present Multiple Abstracts at Paris MASH 2026

5+ day, 3+ hour ago   (847+ words) The Manila Times - Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes - Preclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and…...

Google News
manilatimes.net > 09/09/2026 > tmt-newswire > globenewswire > opko-health-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference > 2420986

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

5+ day, 6+ hour ago   (120+ words) The Manila Times OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today…...

The Manila Times
manilatimes.net > 09/09/2026 > tmt-newswire > globenewswire > radicle-science-expands-leadership-across-science-data-and-health-economics-for-precision-wellness > 2421047

Radicle Science Expands Leadership Across Science, Data, and Health Economics for Precision Wellness

5+ day, 3+ hour ago   (261+ words) Three new scientific leaders and the appointment of former White House Chief Healthcare Economist Jonathan Ketcham, PhD, to the advisory board deepen Radicle’s ability to turn rigorous evidence into precision insights, better health outcomes and measurable economic value SAN DIEGO,…...

The Manila Times
manilatimes.net > 09/08/2026 > tmt-newswire > globenewswire > new-multi-site-validation-study-published-by-panakeia-reinforces-scalability-of-ai-multi-omics-platform > 2420225

New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform

5+ day, 16+ hour ago   (143+ words) Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple cancer types and biomarkers These findings build upon the platform's established success in colorectal cancer (PANProfiler…...

Google News
manilatimes.net > 09/05/2026 > tmt-newswire > globenewswire > bright-minds-biosciences-to-present-at-upcoming-conferences > 2419044

Bright Minds Biosciences to Present at Upcoming Conferences

1+ week, 2+ day ago   (168+ words) The Manila Times Bright Minds Biosciences to Present at Upcoming Conferences NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds,” "BMB” or the "Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment…...

The Manila Times
manilatimes.net > 09/02/2026 > tmt-newswire > globenewswire > newbiologix-and-synastra-biotechnology-partner-to-advance-stable-raav-manufacturing-for-duchenne-muscular-dystrophy-gene-therapy > 2416779

NewBiologix and Synastra Biotechnology Partner to Advance Stable rAAV Manufacturing for Duchenne Muscular Dystrophy Gene Therapy

1+ week, 4+ day ago   (192+ words) Under the agreement, NewBiologix will use its proprietary Xcell™ Stable Manufacturing Platform to generate and characterize a stable Research Cell Bank for Synastra’s DMD gene therapy candidate. The agreement also provides an option to transition the program to a commercial…...

The Manila Times
manilatimes.net > 09/03/2026 > tmt-newswire > globenewswire > helus-pharma-to-participate-at-the-2026-cantor-global-healthcare-conference-in-new-york > 2417840

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

1+ week, 3+ day ago   (481+ words) The Manila Times Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq:…...

The Manila Times
manilatimes.net > 09/03/2026 > tmt-newswire > pr-newswire > aahrpp-accredits-five-more-research-entities > 2417526

AAHRPP Accredits Five More Research Entities

1+ week, 4+ day ago   (173+ words) WASHINGTON, Sept. 3, 2026 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has awarded full accreditation to five more entities, including the U.S. health professions academy and one of the world's leading pharmaceutical companies. The newly accredited entities are: "In…...

The Manila Times
manilatimes.net > 09/02/2026 > tmt-newswire > pr-newswire > btl-establishes-new-laser-division-and-introduces-exolase-one-the-worlds-first-fused-erbium-laser > 2416798

BTL Establishes New Laser Division and Introduces EXOLASE ONE® - The World's First Fused Erbium Laser

1+ week, 4+ day ago   (214+ words) PRAGUE, Sept. 2, 2026 /PRNewswire/ -- BTL, a global leader in advanced energy-based medical and aesthetic technologies, today announced a major milestone in its corporate history: the official establishment of its dedicated laser division and the upcoming launch of its flagship laser system,…...

The Manila Times
manilatimes.net > 09/02/2026 > tmt-newswire > pr-newswire > telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway > 2416651 > amp

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

1+ week, 4+ day ago   (763+ words) The Manila Times - The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. - Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the…...